Welcome to the Annual General Meeting of shareholders of Medicenna Therapeutics Corporation. Please note, the meeting is being recorded. I would like to introduce Dr. Fahar Merchant, Chairman of the board of directors. Dr. Merchant, please go ahead. Good morning, everyone. I welcome you to the annual general meeting of shareholders of Medicenna Therapeutics Corp. My name is Fahar Merchant, and as permitted by our laws, I will act as chairman of the meeting. With the consent of the meeting, I hereby appoint Charles-Antoine Soulière of McCarthy Tétrault LLP, counsel to the corporation, to act as secretary of the meeting. Before moving on to the formal part of the meeting, I would like to introduce the members of the management and the board of directors who are joining us today. Our lead director, Mr. Albert Beraldo, our newly joined board member, Mr. Karim Lalji. We also have, from the management team, our Chief Financial Officer, Jeff Davin, and our Chief Development Officer, Nina Merchant. Before we begin with the formal discussion of the matter to be put to vote today, given that the meeting is being held virtually via live webcast, we think it is necessary to set out a few rules for the orderly conduct of the meeting. As we did last year for our annual shareholder meeting, we chose to hold today's meeting in virtual format only for the sake of efficiency and economy. The corporation has, however, ensured that the required documents were distributed or made available to you in a timely manner. A copy of these documents can be found on the company's webpage by selecting Investor Relations/Financials and Filings/AGM. The corporation has also ensured that all shareholders, regardless of geographic location and equity ownership, have an opportunity to participate at the meeting and engage with the directors of the corporation and management, as well as other shareholders. Please note that today's meeting is being recorded. If you participate in today's meeting and disclose personal information, you'll be deemed to consent to the recording, transfer, and use of same. If you disclose personal information of another person in today's meeting, you'll be deemed to represent and warrant to Lumi and the corporation that you first obtained all required consents for the disclosure, recording, transfer, and use of such personal information from all appropriate persons before your disclosure. Only those who have signed in as a registered shareholder or duly appointed proxyholder with a valid control number are entitled to vote and/or ask questions at this meeting. We'll conduct the votes on all resolutions before the meeting by ballot. On a ballot, every registered shareholder or duly appointed and registered proxyholder entitled to vote has one vote in respect of each common share entitled to be voted on the matter and held or represented by that registered shareholder or duly appointed proxyholder. Since voting on each resolution is by ballot, I will be voting all undirected proxies that I am permitted to vote in favor of all resolutions before the meeting. Voting is now open, and all registered shareholders and duly appointed and registered proxyholders should have the functionality and ability to cast votes at any time during the meeting until we declare voting closed. Thank you to those of you who have already voted. If you have already voted in advance of the meeting and do not wish to change your vote, then you do not need to do anything further at the meeting. For those who have not yet voted, we encourage you to vote now. If you choose to vote during this meeting, it only can be done through the virtual voting platform on the webcast. To vote, select the Voting button located at the left side of the screen and click the desired voting option. Votes may be changed at any time up to the time of voting is closed. Once voting is declared closed, you will not be able to cast your votes. Please ensure you choose For, Against, or Withhold, as applicable, to ensure your votes are received by the scrutineers. Also, registered shareholders and duly appointed proxyholders who have logged in with a valid control number can submit questions at any time during the meeting through the virtual platform of our webcast. We will address questions at a general Q&A session at the end of the formal part of the meeting, provided that only questions regarding procedural matters or questions directly related to the resolutions before the meeting may be addressed during the meeting. We will receive the questions, and at the appropriate time, we'll read them and the names of the submitting shareholders or proxyholders aloud so that everyone may be aware of the question being considered. In the interest of efficiency, if we have a number of questions that are similar in topic, we will group the questions and mention that we have received similar questions. However, please note that due to time constraints, we may be unable to answer or address all questions. This meeting has also been made accessible too, and we also wish to welcome all guests who are not registered shareholders or holding proxies of registered shareholders. As a reminder, as with any in-person meeting, only registered shareholders and duly appointed and registered proxy holders are permitted to vote or ask questions at this meeting. In order to make the best use of our time, Mr. Albert Beraldo will move, and I will second all motions. While this procedure will facilitate the handling of the formal matters, registered shareholders or duly appointed proxy holders may address the meeting when there is a call to discuss a motion before the meeting. Should you like to address the chairman on any motion, please type in your question or comment in the messaging tab available on the top left side of your screen. A reminder that this function is only available to those who have logged in as a registered shareholder or duly appointed proxy holder. If there is any discussion or question, the secretary will read the question aloud. All motions will be moved and seconded once the formal matters of the meeting have been presented. With the consent of the meeting, Odyssey Trust Company, the corporation's transfer agent and registrar, through its representatives, will act as scrutineers of this meeting. The scrutineers will report on the shareholders present on the virtual platform and the number of securities represented in person and by proxy at this meeting, complete the votes cast by ballot, and report to me on these matters. I have received the preliminary scrutineers' report. I declare that there are at least two shareholders present by electronic means and holding or representing by proxy at least 25% of the votes entitled to be cast at the meeting. As such, I declare that the requisite quorum of shareholders is present and that the meeting is properly constituted for the transaction of its business. I direct that the scrutineers' report on attendance be annexed to the minutes of the meeting. The purpose of today's meeting is set out in detail in the management information circular dated August 14th, 2024. Access to the notice calling this meeting and the accompanying materials has been provided to all shareholders of the corporation, and I have here the certificate of our transfer agent, Odyssey Trust Company, indicating that proper notice of the meeting has been mailed in accordance with the Canada Business Corporations Act, the bylaws of the corporation, and the Notice and Access Regime. Copies of such materials are available on Medicenna's website and under Medicenna's profile on SEDAR+. Accordingly, unless there is an objection, the reading of the notice of meeting will be dispensed with. I direct that a copy of the notice of meeting, together with proof of the mailing, be kept by the secretary with the records of the meeting. I propose that we proceed with the business of the meeting. The 2024 annual report of the corporation for the fiscal year ended March 31st, 2024, together with the 2024 audited financial statements and the related auditor's report, have been mailed to the shareholders of the corporation who previously requested them in accordance with the Notice and Access Regime. Copies of such materials are available on Medicenna's website and under Medicenna's profile on SEDAR+. It is not intended nor required to ask shareholders to approve the financial statements. However, management would be pleased to deal with any relevant questions concerning the statements during the general question period, which follows the formal business of this meeting. We will now proceed with the election of directors. The proposed nominees to the board of directors are Albert Beraldo, Karen Dawes, Jack Geltosky, John Buchan, Karim Lalji, and myself, Fahar Merchant. I understand that these nominees have consented to act as directors. The next item of business is to appoint MNP LLP as the auditor to hold office until the close of the next annual general meeting of shareholders or until its successor is appointed, and that the directors of the corporation be authorized to fix its remuneration in such amounts as the directors may, in their discretion, determine. Now that all formal matters of the business have been presented, would Albert Beraldo please make the motions for the formal matters of the meeting? Albert? Mr. Chairman, first, I move that the persons that have been nominated be individually elected as a director of Medicenna Therapeutics Corp for the ensuing year or until their successors are elected or appointed. And second, I move that MNP LLP be appointed as auditor for Medicenna Therapeutics Corp for the fiscal year ending March 31st, 2025, and that the directors of the corporation be authorized to fix its remuneration. Thank you, Mr. Beraldo. I second all of Mr. Beraldo's motions. Mr. Secretary, are there any questions or discussions on these motions? There is no discussion at this time. As there is no discussion, I now call for a vote to the motions before the meeting. As previously mentioned, voting today will be conducted by ballot. The ballot has been open since the beginning of the meeting, and at this point, all registered shareholders and duly appointed and registered proxyholders who have properly logged in with their control numbers and wish to vote, should make their way to the Voting tab located on the left side of the screen. There, they will be able to see on the screen all the items put forward before this meeting. The voting will remain open for an additional thirty seconds. Once the ballot closes, you will no longer be able to submit your votes. Now, before announcing the voting results, Mr. Secretary, is there any other business that any shareholder or proxyholder present wishes to bring to the attention of the meeting? There is no discussion at this time. If there is no further business, I now declare the ballot closed, and we will proceed to present the voting results. I will now ask the secretary to provide the preliminary results of the scrutineers' tabulation of today's votes. Thank you, Mr. Chairman. The scrutineers confirmed the following preliminary vote results. Each of the director nominees received the required percentage of votes for, and the percentage of required votes are favorable to the appointment of MNP LLP as auditor for Medicenna Therapeutics Corp. for the fiscal year ending March 31st, 2025. Thank you. I declare each of the resolutions considered at today's meeting in respect of those matters as carried. The final report on voting results will be provided by the scrutineers after the meeting and will be incorporated into the minute, minutes of the meeting. The percentage of votes counted for the election of directors will be disclosed in a press release and a report of voting results that will be filed later today under Medicenna's profile on SEDAR+. That concludes the formal business of this annual general meeting of the shareholders, which I now declare closed. On behalf of the board of directors, I would like to thank... I would like to take the opportunity to thank everyone for attending the meeting today. I would also like to thank all of our shareholders for their commitment and support, our employees, our advisors, our directors, and more importantly, all the patients that have been participating in our clinical trials. Thank you for participating in today's meeting. We look forward to keeping you up to date as we progress with our program.